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Available online 12 January 2016Several non-animal methods are now available to address the key events leading to skin sensitization as deﬁned
by the adverse outcome pathway. The KeratinoSens™ assay addresses the cellular event of keratinocyte activa-
tion and is a method accepted under OECD TG 442D. In this study, the results of an inter-laboratory evaluation
of the “me-too” LuSens assay, a bioassay that uses a human keratinocyte cell line harboring a reporter gene con-
struct composed of the rat antioxidant response element (ARE) of the NADPH:quinone oxidoreductase 1 gene
and the luciferase gene, are described. Earlier in-house validation with 74 substances showed an accuracy of
82% in comparison to human data. When used in a battery of non-animal methods, even higher predictivity is
achieved. To meet European validation criteria, a multicenter study was conducted in 5 laboratories. The study
was divided into two phases, to assess 1) transferability of the method, and 2) reproducibility and accuracy.
Phase I was performed by testing 8 non-coded test substances; the results showed a good transferability to
naïve laboratories even without on-site training. Phase II was performed with 20 coded test substances (perfor-
mance standards recommended by OECD, 2015). In this phase, the intra- and inter-laboratory reproducibility as
well as accuracy of themethodwas evaluated. The data demonstrate a remarkable reproducibility of 100% and an
accuracy of over 80% in identifying skin sensitizers, indicating a good concordancewith in vivo data. These results
demonstrate good transferability, reliability and accuracy of the method thereby achieving the standards neces-
sary for use in a regulatory setting to detect skin sensitizers.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Allergic contact dermatitis, the clinically relevant outcome of skin
sensitization, is one of the most prevalent skin diseases. It is estimated
that 15–20% of the general population will be sensitized to at least one
substance at some point during the course of their lives (Thyssen
et al., 2007; Bruckner et al., 2000) with the prevalence possibly increas-
ing (Lunder and Kansky, 2000; Nguyen et al., 2008). Assessment of the
skin sensitization potential (hazard) of a substance is therefore a keyedel).
. This is an open access article underendpoint in human health hazard assessments. Traditionally, the evalu-
ation of the skin sensitization hazard of a substance in a regulatory set-
ting has been achieved by the use of the guinea pig based tests (OECD
TG 406) and the mouse-based local lymph node assay (LLNA, OECD
TGs 429, 442A, 442B). Due to the animal testing and marketing bans
enforced by the 7th amendment to the Cosmetics Directive (now
Cosmetics Regulation: 1223/2009), the increasing awareness on the
ethical aspects of animal testing and the desire to better understand
the mechanistic basis of the sensitization process, much effort has
been put into the development of non-animal testing methods for this
endpoint. Currently, two non-animal test methods, the direct peptide
reactivity assay (DPRA, OECD 442C) and the Keratinocyte-based ARE–the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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the KeratinoSens™ assay) have been adopted as OECD test guidelines
in 2015 (TG 442 C and 442D, respectively). The human cell line activa-
tion test (h-CLAT) is in draft and can now be used in integrated assess-
ments and testing approaches (IATA) in particular in adverse outcome
pathway (AOP) based strategies (OECD, 2012, parts 1 and 2).
Recently, the LuSens assay, which utilizes a reporter cell line to de-
tect the activation of theNrf2 pathway (Ramirez et al., 2014) has proven
to discriminate efﬁciently skin sensitizers from non-sensitizers. The
LuSens assay employs a principle similar to the KeratinoSens™ assay
(Emter et al., 2010) in that a Nrf2/Keap1 dependent Antioxidant
Response Element (ARE) luciferase reporter gene is used to assess in-
duction of the ARE pathway.
Although animal welfare is of major importance, ensuring human
health is paramount. Therefore, the suitability of a test method for reli-
able hazard assessmentsmust be substantiated. Formal validation dem-
onstrates not only the predictive capacity but also reproducibility and
transferability to other laboratories and thereby contributes to the in-
ternational acceptance and use of test methods. As an alternative to
the currently validated ARE–Nrf2 luciferase test, the LuSens assay was
developed. Its predictive capacity towards skin sensitizer potential has
been reported previously (Ramirez et al., 2014; Urbisch et al., 2015).
In the current study, the intra- and inter-laboratory reproducibility
and transferability of the LuSens assaywere assessed in ﬁve laboratories
located in Germany, Switzerland and theUSA. The results demonstrated
that the assay is robust, reliable and accurate for the identiﬁcation of
skin sensitizer hazard.
2. Material and methods
2.1. Study plan
BASF Experimental Toxicology and Ecology as the leading laboratory
invited six laboratories to participate in the validation study. Two of
these faced capacity problems, so that four laboratories successfully
completed Phase I (transferability) and were able to proceed to Phase
II. The participating laboratories were: Burleson Research Technologies
Inc. (BRT, USA); DSM Nutritional Products AG (DSM, Switzerland);
The Procter & Gamble Company (P&G, USA) and the Institute for In
Vitro Sciences Inc. (IIVS, USA). The only laboratory to receive a one
week training prior to testing was DSM; the remaining laboratories
established the method with the help of the LuSens assay protocol and
clariﬁcations via telephone conference with the lead laboratory. More-
over, someof them (P&Gand IIVS) had previous experiencewith the es-
tablishment of the KeratinoSens™ assay. During Phase I, eight non-
coded test items were tested in one experiment each; an experiment
consisted of a range ﬁnder assay and two concordant repetitions of
the main assay. For this phase, the lead laboratory provided a detailed
protocol, analysis data sheets and cell passage control data sheets. The
protocol was discussed in detail prior to initiation of the transferability
phase. The following criteria (deﬁned a-priori), had to be met by the
laboratories in order to proceed to Phase II: Each laboratory had to
a) perform the required number of valid repetitions (at least two per ex-
periment), and b) predict the sensitization potential of at least six test
substances of the eight substances correctly. After completion of Phase
I, the data were analyzed and it was determined which of the laborato-
ries could continue to Phase II. Phase II was performed with 20 coded
test substances (Performance standards for assessment of proposed
similar or modiﬁed in vitro skin sensitization ARE–NRF2 luciferase test
method. Series on Testing and Assessment No. 213, OECD, 2015).
The codewas generated by an independent third party and assigned
to the test substances.
To reduce the workload of the laboratories, while still meeting the
performance standard (PS) requirements, the following experimental
designwas selected: 12 of 20 PS substances were tested in three labora-
tories (lead laboratory, laboratories 1 and 2) in three independentexperiments, for the within laboratory reproducibility (WLR) assess-
ment, whereas the remaining eight test substances were tested in
three laboratories (lead laboratory, laboratories 3 and 4) in one experi-
ment. Laboratories 3 and 4 tested also ﬁve of the 12 WLR test
substances.
2.2. Test substances
All test substances used in this study were ordered from Sigma,
whereby the Sigma supplier was Aldrich, Fluka or Sigma-Aldrich
(Table 1). The substances used in this study were alpha-hexyl-
cinnamic aldehyde, 2-mercapto-benzothiazole, 1-chloro-2,4-dinitro-
benzene; 4-methoxy-acetophenone; 4-(methylamino)phenol sulfate
(metol); 4-nitrobenzyl bromide; chlorobenzene; citral; ethylene glycol
dimethacrylate; eugenol; glycerol; isoeugenol; isopropanol; DL-Lactic
acid; methyldibromo glutaronitrile; methyl salicylate; oxazolone;
para-phenylenediamine, phenyl benzoate, salicylic acid and sulfanil-
amide (Table 1), as proposed by OECD for the validation of a me-too
assay (OECD, 2015). Phase I substances were acquired, aliquoted and
shipped by the lead laboratory. Phase II substances were acquired by
the lead laboratory but coded and shipped to all laboratories by an inde-
pendent company. To prevent identiﬁcation of the test substance based
on the exact molecular weight (MW), test substances were provided
with approximate MWs (Table S1; supplement).
2.3. Cell line maintenance and propagation
LuSens cells, a human keratinocyte cell line (provided by RWTH, Aa-
chen, Germany, Ramirez et al., 2014), were stored in liquid nitrogen
until thawing the cryovial in a 37 °C water bath. As soon as the ice
melted, cells were gently resuspended in 20 mL of Dulbecco’s Modiﬁed
Eagle Medium (DMEM, Biochrom, Germany) supplemented with 10%
fetal bovine serum (FBS; Superior; Biochrom, Germany or comparable)
and 1% penicillin/streptomycin and seeded in T75 culture ﬂasks at a
density of ~1.5–2 × 106 per ﬂask. After 24 h, the cell culture media
was replaced by 20 mL of DMEM supplemented with 10% FBS, 1% pen-
icillin/streptomycin and 0.005% puromycin. Cells were propagated, ali-
quots frozen and an aliquot kept in culture to generate a master and
working bank that was used for all experiments performed for the
study. For cell maintenance, cells were cultivated in T75 ﬂasks with
20 mL of growthmedia (DMEMwith 10% FBS, 1% penicillin/streptomy-
cin, and 0.005% puromycin (all components from Biochrom, Germany
except puromycin, which was obtained from Sigma, Germany), at
37 °C in a humidiﬁed atmosphere containing 5% CO2 and allowed to
grow to a conﬂuence of 80–90%. Cells were split twice a week by
trypsinization (0.05% trypsin/0.02% EDTA solution; Biochrom,
Germany) and seeded at a density of 0.68 × 106 (for those experiments
starting on Monday) or 0.4 × 106 cells (for experiments starting on
Tuesday) in T75 cultureﬂasks containing 20mLof culturemedia and in-
cubated at 37 °C in a humidiﬁed atmosphere containing 5% CO2.
2.4. Procedure
The LuSens assay uses similar steps as the KeratinoSens™ or h-CLAT
assay (Emter et al., 2010; Nukada et al., 2012) and consists of two
phases: a range ﬁnder experiment and a main experiment. The range
ﬁnder is used to select the adequate dose range that will be tested in
the main experiment. Therefore, in the range ﬁnder only viability is
measured using theMTT assay. Based on the results of the range ﬁnder,
the concentration inwhich cell viability corresponds to no less than 75%
(CV75) is calculated. The highest tested concentration in the main ex-
periment is then 1.2× CV75 (dilution series CV75/2.074; CV75/1.728;
CV75/1.44; CV75/1.2; CV75 and 1.2× CV75) or 2000 μM if no cytotoxic-
ity is observed. For range ﬁnder experiments, LuSens cells are used for
pre-culture at passage 4 to passage 15, and 80–90% conﬂuence. Cells
are trypsinized and resuspended in 9 mL DMEM containing 10% FBS.
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well of a clear ﬂat bottom 96 well plate. Cells are incubated for 24 h at
37 °C in a humidiﬁed atmosphere containing 5% CO2. Prior to treatment,
cell culture media is replaced with 150 μL of fresh media containing 1%
FBS, moreover, test substances are dissolved in DMSO to prepare stock
solutions, 12 mM ethylene glycol dimethylacrylate (EGDMA as positive
control (PC), Sigma, Germany), and 500 mM DL-lactic acid (DL-LA as
negative control (NC), Fluka, Germany). 200 mM stock solution
(100×) of test substances are prepared. For treatment, 50 μL of the
test substance dilutions are applied to have in triplicate following test
concentrations: 0.976, 1.953, 3.906, 7.812, 15.625, 31.25, 62.5, 125,
250, 500, 1000 and 2000 μM and 120 μM EGDMA and 5000 μM DL-LA.
The plates are sealed with a breathable tape (Nunc/Thermo, Germany)
and incubated for 48 h at 37 °C in a humidiﬁed atmosphere containing
5% CO2. After 48 h treatment, viability is measured by means of the
MTT assay (Mosmann, 1983). Then the concentration at which the via-
bility is reduced to no more than 75% (CV75) compared to vehicle con-
trol (VC) is calculated.
For the main experiment, the expression of luciferase at non-
cytotoxic concentrations is evaluated. Brieﬂy, cells were seeded into
clear and white ﬂat bottomed 96 well plates (Perkin Elmer,
Switzerland) at 1 × 104 cells in 120 μL per well. The cells seeded in
clear plates were used for the MTT cytotoxicity assay, whereas, the
white plates for the luciferase assay. Prior to treatment, cells were incu-
bated for 24 h at 37 °C in a humidiﬁed atmosphere containing 5% CO2.
For treatment, test substances were dissolved in DMSO (100× stock so-
lution) at concentrations determined from the preliminary cytotoxicity
data. Substances were further diluted (1:25) in DMEM containing only
1% FBS to obtain 4× stock solution. Final in-well DMSO concentration
should not exceed 1%. The highest tested concentration is 1.2× CV75 (di-
lution series CV75/2.074; CV75/1.728; CV75/1.44; CV75/1.2; CV75 and
1.2× CV75). Treatment was performed by adding 50 μL of the test sub-
stance dilution to each well which already contains 150 μL of media
(ﬁnal volume: 200 μL) and incubating for 48 h. Each substancewas tested
at six concentrations in triplicate. Positive and negative controls were
prepared as indicated in the range ﬁnder experiment and dosed in a sim-
ilar fashion. After treatment, ARE activation was measured by luciferase
assay (Steady-Glo® or One-Glo® Assay System; Promega, Germany/
USA) using a luminometer. The fold induction (FI) of the luminescent sig-
nal is calculated by dividing the relative luminescence units (RLU) of the
treated cells (TC) by the RLU of vehicle control (VC) treated cells using
the following equation: FI = (RLU TC) / (RLU VC). In parallel, the MTT
assaywas performed as indicated above for the range ﬁnder experiment.
An experiment consisted of at least two independent repetitions
(runs) of the MTT and luciferase assays. If the classiﬁcation of the two
runs were discordant, a third run was conducted.
A detailed description of all steps included in this protocol can be
found in the LuSens training video: (http://cops.basf.com/basfcorp/
img/alternatives/videos/toxikologie/lusens_en.html)
2.5. Controls and acceptance criteria
The LuSens assay uses as PC, EGDMA at the concentration of 120 μM.
Should a toxicity above 30% be observed, then a range ﬁnder experi-
ment with decreasing concentrations of EGDMA was performed in
order to select the appropriate concentration of the PC that induces lu-
ciferase above 2.5 fold and leads to a viability above 70%. In addition, a
NC, DL-LA at the concentration of 5000 μM is tested concurrently.
In addition to the performance of the PC and NC controls, various
validity criteria were also established to evaluate if a repetition is suit-
able for evaluation (Table 2).
2.6. Prediction model
Each valid repetition (i.e. meeting all acceptance criteria, according
to the procedure described above) was interpreted as follows:A test substance was considered to have sensitizing potential when
the luciferase induction was greater than or equal to 1.5 fold compared
to the vehicle control in at least two consecutive non-cytotoxic concen-
trations and at least three concentrations must be non-cytotoxic. A test
compound was considered to not have a sensitizing potential if the
above effects were not observed.
In order to conclude on the skin sensitization hazard of a substance,
one complete experiment needed to be conducted. A complete experi-
ment consisted of two valid independent repetitions according to the
above-described acceptance criteria. If the ﬁrst two repetitions were
concordant (i.e. either being negative or being positive) no further test-
ing was required. In case that the ﬁrst two repetitions gave discordant
results (i.e. one is negative and the other is positive), a third indepen-
dent repetition was conducted to complete the experiment.
The skin sensitizing potential of a test substance was determined by
the result of the majority of the repetitions of an experiment. If two of
two or two of three repetitions were negative/positive, the substance
was considered as negative/positive.
2.7. Data analysis and statistical evaluation
The designated study directors submitted all appropriately docu-
mented data analysis sheets to BASF. BASF forwarded this information
to an independent statistician for analysis. The analysis was based on
data derived from testing the 20 PS recommended by OECD for the as-
sessment of proposedmethods similar to (me-too) ormodiﬁed versions
of the “in vitro skin sensitization ARE–Nrf2 luciferase test methods”
(OECD, 2015).
The predictive parameters sensitivity, speciﬁcity, positive and nega-
tive predictive value and accuracy were derived from 2 × 2 contingency
tables to describe the predictive capacity: sensitivity: (True positive
(TP) / [TP + False Negative (FN)] × 100); speciﬁcity: (True negative
(TN) / [TN + False positive (FP)] × 100); positive predictive value:
(TP / [TP + FP] × 100); negative predictive value:((TN / [TN + FN] ×
100); and accuracy: ([TP + TN] / [TN + TP + FP + FN] × 100) with
FN being the number of false negative calls, FP the number of the false
positive calls, TN the number of the true negative calls and TP the num-
ber of the true positive calls.
3. Results
The LuSensmethodwas initially validated for its predictivity and ac-
curacy in identifying potential skin sensitizers by testing more than 74
test substances (Ramirez et al., 2014). In the study reported here, the
inter-laboratory validation of the LuSens assay was assessed. The
study was performed with ﬁve international laboratories; one located
in Germany, one in Switzerland and three in the USA and was designed
to assess the transferability, and WLR and between laboratory repro-
ducibility (BLR) of the LuSens assay.
3.1. Phase I: transferability of the method
In Phase I, the method was transferred to other laboratories by
provision of the standard operating protocol (SOP) and a conference call
with the method developer to explain the SOP. No on-site training was
conducted, except for one laboratory, as previouslymentioned, two labo-
ratories had previous experience in working with KeratinoSens™ assay.
For each laboratory, the success of the transferability was judged based
on the amount of valid and invalid repetitions obtained from the
whole testing, as well as according to the predictive capacity (at least 6
of the 8 substances should be predicted correctly). For this purpose,
each individual repetition was evaluated according to the validity
criteria of Table 2. However, it is important to note that during the ﬁrst
set of repetitions performed by the testing laboratories, it became
evident that additional issues related to cell viability occurred, in order
to avoid those viability problems; criterion vii was deﬁned after the
Table 1
Test substances used to evaluate the between laboratory reproducibility during the inter-laboratory validation of the LuSens assay.
Chemical information Human data LLNA data
No. Substance Molecular
weight
[g/mol]
Purity
(%)
Supplier CAS # Physical
state
Chemical class Mechanism Literature Pro/prehapten Human Literature EC3
(%)
Potency
class
LLNA Literature
1 Alpha-hexyl-cinnamic
aldehyde
216.3 97.1 Aldrich 101-86-0 Solid Aldehyde Michael
acceptor
Patlewicz et al. (2008) + Basketter et al.
(1999)
8 Moderate + Kimber et al.
(2003)
2 2-Mercaptobenzothiazole 167.2 97.0 Aldrich 149-30-4 Solid Thiazole/heterocyclic SN2 agent Roberts et al. (2007) + Basketter et al.
(1999)
9.7 Moderate + Kimber et al.
(2003)
3 1-Chloro-2,4-dinitrobenzene 202.6 99.6 Aldrich 97-00-7 Solid Nitroaromatic,
aromatic halide
SNAr agent Patlewicz et al. (2008) + Basketter et al.
(1999)
0.049 Extreme + Kimber et al.
(2003)
4 4-Methoxyacetophenone 150.2 99.0 Aldrich 100-06-1 Solid Ketone ether Non-binding Patlewicz et al. (2008) − Gerberick
et al. (2001)
NC Non − Gerberick
et al. (2005)
5 4-(Methylamino) phenol
sulfate (Metol)
172.19 ≥99.0 Fluka 55-55-0 Solid Aromatic alcohol,
aromatic amine
Precursor
quinone
Aptula et al. (2009),
Roberts et al. (2007)
Pre/pro-MA + Basketter et al.
(2014)
0.8 Strong + Basketter et al.
(2014)
6 4-Nitrobenzyl bromide 216.0 99.0 Aldrich 100-11-8 Solid Benzyl halide SN2 agent Roberts et al. (2007) No suitable
data available
n.d. n.d. + ICCVAM,
(1999)
7 Chlorobenzene 112.6 99.9 Sigma-Aldrich 108-90-7 Liquid Aromatic halide Non-binding Patlewicz et al. 2008 − OECD TG 429
(2010)
NC Non − Gerberick
et al. (2005)
8 Citral 152.2 96.5 Aldrich 5392-40-5 Solid Aldehyde/terpenoids Schiff base Patlewicz et al. (2008) + Basketter et al.
(1999)
13 Weak + Kimber et al.
(2003)
9 Ethylene glycol
dimethacrylate
198.2 98.2 Aldrich 97-90-5 Liquid α,β-Unsaturated
ester
Michael
acceptor
Patlewicz et al. (2008) + Basketter et al.
(1999)
35 Weak + Kimber et al.
(2003)
10 Eugenol 164.2 99.0 Aldrich 97-53-0 Solid Phenylpropanoid Quinone
precursor
Patlewicz et al. (2008) Pre/pro-MA + Basketter et al.
(1999)
13 Weak + Gerberick
et al. (2005)
11 Glycerol 92.1 99.5 Sigma 56-81-5 Liquid Aliphatic alcohol Non-binding Patlewicz et al. (2008) − Basketter et al.
(1999)
100.02 Non − Natsch and
Emter. (2008)
12 Isoeugenol 164.2 99.0 Aldrich 97-54-1 Solid Phenylpropanoid Quinone
precursor
Aptula et al. (2006) Pre/pro-MA + Basketter et al.
(1999)
1.5 Moderate + Kimber et al.
(2003)
13 Isopropanol 60.1 99.5 Sigma 67-63-0 Liquid Aliphatic alcohol Non-binding Patlewicz et al. (2008) - Basketter et al.
(1999)
NC Non − Gerberick
et al. (2005)
14 DL-Lactic acid 90.1 91.2 Fluka 50-21-5 Liquid Organic acid,
aliphatic alcohol
Non-binding Patlewicz et al. (2008) - Basketter et al.
(1999)
NC Non − Gerberick
et al. (2005)
15 Methyldibromo
glutaronitrile
265.9 98.0 Fluka 35691-65-7 Solid Nitrile/alkyl halide SN2 agent Author's data + SCCP (2005) 0.9 Strong + Basketter et al.
(2008)
16 Methyl salicylate 152.1 99.6 Sigma-Aldrich 119-36-8 Liquid Aromatic ester Non-binding Patlewicz et al. (2008) − Basketter et al.
(1999)
NC Non − Gerberick
et al. (2005)
17 Oxazolone 217.2 98.0 Fluka 15646-46-5 Solid Oxazole Acylating
agent
Patlewicz et al. (2008) + Basketter et al.
(1999)
0.003 Extreme + Kimber et al.
(2003)
18 Para-phenylenediamine 108.1 97.0 Aldrich 106-50-3 Solid Aromatic amine Quinone
precursor
Patlewicz et al. (2008) Pre/pro-MA + Basketter et al.
(1999)
0.16 Strong + Gerberick
et al. (2005)
19 Phenyl benzoate 198.2 99.4 Aldrich 93-99-2 Solid Benzoate (ester) Acylating
agent
Patlewicz et al. (2008) + OECD TG 429
(2010)
20 Weak + Gerberick
et al. (2005)
20 Salicylic acid 138.1 99.0 Sigma-Aldrich 69-72-7 Solid Aromatic alcohol,
Organic acid
Non-binding Patlewicz et al. (2008) − Basketter et al.
(1999)
NC Non − Gerberick
et al. (2005)
21 Sulfanilamide 172.2 99.8 Sigma-Aldrich 63-74-1 Solid Aromatic sulfon,
aromatic amine
Non-binding Patlewicz et al. (2008) − Basketter et al.
(1999)
NC Non − Gerberick
et al. (2005)
LLNA: local lymph node assay; +: sensitizers;−: non-sensitizer; NC: no concentration; n.d.: non-determined; MA: Michael acceptor.
281
T.Ram
irez
etal./Toxicology
in
V
itro
32
(2016)
278–286
Table 2
Acceptance criteria to determine repetition validity (i.–iv, vi, vii) and qualiﬁcation for evaluation (v).
Criterion Description
i. Induction of the blank-corrected positive control, i.e. 120 μM EGDMA: on average ≥2.5 fold (compared to the blank-corrected solvent control)
ii. Induction of the blank-corrected negative control, i.e. 5000 μM DL-Lactic acid: on average b1.5 fold (compared to the blank-corrected solvent control)
iii. Coefﬁcient of variation (CV) of the solvent control (at least 21 of a total of 24 luminescence measurementsa): ≤20%
iv. At least three non-cytotoxic, i.e. cell viability ≥70%, test substance concentrations
v. In case of a negative response, at least one concentration must be cytotoxic, i.e. have a cell viability b70%, or the maximum concentration of 2000 μMmust have been tested
vi. Mean basal expression of the blank (only cells): b1.5 fold (compared to the blank-corrected solvent control)
vii. Mean cell viability of blank-corrected positive control (PC): ≥70% (compared to the viability of the blank-corrected solvent control)⁎
a Outlier is eliminated from the calculation by performing an outlier check based on the minimum and maximum fold induction values obtained in the vehicle control treated cells.
⁎ This criterion was developed during Phase I and only used for the assessment of Phase II.
282 T. Ramirez et al. / Toxicology in Vitro 32 (2016) 278–286initiation of Phase I (Table 2). As this criterionwas established after test-
ing had been initiated, it was not used for the ﬁnal assessment of the lab-
oratories that should continue on to Phase II of the study. For this reason,
the assessment of a repetition's validitywas based on theoriginal criteria
only (i–vi).
Not all laboratories conducted the same number of repetitions: lab-
oratory 4 performed the highest number of repetitions (40) and labora-
tory 2 performed the lowest number of repetitions (21). As previously
mentioned, determination of the validity of the results of each repeti-
tion was performed using the original criteria (i–vi) and the following
percentages of valid repetitions was attained: 90; 100; 95; 79 and 73%
for the lead laboratory, laboratories 1, 2, 3 and 4, respectively (Table 3).
In general the major reason for invalidity of repetitions were high
cytotoxicity (criteria iv, Table 2) and high CV of the VC treated cells
(criteria iii, Table 2). The ﬁrst issue can be explained by technical prob-
lems with the preparation and dilution of stock solutions of potential
cross-contamination of the wells due to improper adhesion of the tape
to the plates. Regarding high CV of VC samples, it was realized that the
potential source of the problem was the luminometer used, that lead
to lowRLUvalues. This problemwas approached as follows: a) the lucif-
erase reagent was changed from Steady Glo™ to OneGlo™ in order to
enable the yield higher RLU values, and b) use of another luminometer
in which the settings could be customized.
All laboratories had a high percentage of valid repetitions, which
exceeded 70%, thereby meeting one of the two criteria needed for con-
tinuation in Phase II.
In addition to the number of valid repetitions, a second criterion to
continue on to Phase II was deﬁned by the lead laboratory, namely the
testing laboratories should correctly predict at least 6 of the 8 test sub-
stances. When analyzing the data on this regard, it was observed that,
the lead laboratory, laboratories 1 and 2 obtained correct predictionsTable 3
Summary of all performed repetitions per testing laboratory. Numbers of total and invalid exper
the LuSens assay according to the PS (n.a.: not applicable; incl.: including; PI: Phase I).
Phase I (PI)
Laboratory
Lead 1
No. of experiment (total) 8 8
No. of repetitions (total) 30 24
Repetitions invalid (i–iv, vi, vii) or not qualiﬁed for evaluation (v) i) 0 0
ii) 0 0
iii) 2 0
iv) 1 0
v) 0 0
vi) 0 0
vii) n.a. n.a.
Repetitions invalid or not qualiﬁed for evaluation: proportion 3/30 0/24
Repetitions invalid or not qualiﬁed for evaluation: % 10.0 0.0
Repetitions valid or qualiﬁed for evaluation: % 90.0 100.0for 6 test substances, laboratory 3 for 7 test substances and laboratory
4 for the 8 test substances. Therefore, all testing laboratories met the
second criterion on the predictive capacity required to continue with
Phase II of the study.3.2. Phase II: assessment of validity of repetitions, within-, between-
laboratory reproducibility and accuracy of the assay
The 20 PS recommended by the OECD (OECD, 2015) were used for
the assessment of theWLR and BLR of this study. Due to the speciﬁc de-
sign of this study, 12 of 20 PS substances were tested in three laborato-
ries (lead laboratory, laboratories 1 and 2) in three independent
experiments, for WLR assessment, whereas the remaining 8 test sub-
stances were tested in 3 laboratories (lead laboratory, laboratories 3
and 4) in one experiment. Furthermore, laboratories 3 and 4 tested
also 5 of the 12 WLR test substances. The reproducibility was assessed
based on the concordance of predictions.
Prior to the assessment of reproducibility, all data was evaluated for
validity. For this purpose, all repetitionswere evaluated according to the
criteria in Table 2. The number of experiments performed by the lead
laboratory, laboratories 1, 2, 3 and 4 was 44, 40, 36, 14 and 18, respec-
tively. This led to 96, 95, 73, 32 and 35 independent repetitions per-
formed by the lead laboratory, laboratories 1, 2, 3 and 4, respectively.
The number of invalid or not qualiﬁed repetitions for evaluation was
3/96 (3.1%), 18/95 (19.0%), 0/73 (0.0%), 5/32 (15.6%) and 8/35 (22.9%)
for the lead lab, laboratories 1, 2, 3 and 4, respectively (For details,
please see Table 3). In summary, the frequency of non-valid and/or
non-qualiﬁed repetitions was 0-23%, being below 25% in all cases,
which was comparable to the proportion of validity repetitions ob-
served in Phase I of the study.iments and absolute and relative amounts of (in-) valid repetitions from the assessment of
Phase II
Laboratory
2 3 4 Lead 1 2 3 4
8 8 8 44 40 (incl. 2 from PI) 36 (incl. 3 from PI) 14 18
21 33 40 96 95 73 32 35
0 0 0 0 0 0 0 0
0 4 0 0 0 0 0 0
0 4 10 0 0 0 1 0
0 0 0 2 11 0 2 1
1 0 0 0 4 0 2 1
0 2 4 1 1 0 0 0
n.a. n.a. n.a. 0 3 (all from PI) 0 0 6
1/21 7/33 11/40 3/96 18/95 0/73 5/32 8/35
4.8 21.2 27.5 3.1 19.0 0.0 15.6 22.9
95.2 78.8 72.5 96.9 81.0 100.0 84.4 77.1
Table 5
Predictions of the 20 reference substances ofﬁve laboratories. In caseswith three indepen-
dent experiments, the mode is reported (+: positive/skin sensitizer prediction;−: nega-
tive/non-sensitizer prediction; nt: not tested; #: experiments conducted in the
transferability phase; *:experiments with three repetitions).
Test substances Laboratory
Lead Lab1 Lab2 Lab3 Lab4
2-Mercaptobenzothiazole + nt nt + +
2,4-Dinitrochlorobenzene + + +# + +
4-Methoxy-acetophenone + + + nt nt
4-Methylaminophenolsulfate + nt nt +* +
4-Nitrobenzylbromide + + + nt nt
Chlorobenzene −* nt nt − −
Citral + +# +# nt nt
Ethylene glycol dimethacrylate + +# +# nt nt
Eugenol +* nt nt + +
Glycerol − − − − −
Isoeugenol + + + nt nt
Isopropanol − − − − −
Lactic acid −* nt nt - -
Methyldibromo glutaronitrile + + + + +
Methyl salicylate +* nt nt + +
Oxazolone + nt nt + +
Para-phenylenediamine + + + nt nt
Phenyl benzoate − − − nt nt
Salicylic acid − − − − −
Sulfanilamide − nt nt − −
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The WLR was assessed according to the PS requirements. It was
based on the concordance of predictions of three independent experi-
ments for the subset of 12 reference substances, i.e. a total of 36 exper-
iments/laboratory. Concordance was evaluated without taking the
reference results into account. The three laboratories lead, 1 and 2 con-
sistently classiﬁed the 12 substances in three independent experiments
(Table 4). Therefore, the laboratory-speciﬁc and the overall WLR were
12/12 = 100%.
In addition to the PS requirements, additional aspects relevant for
the WLR assessment were considered. First, the concordance of predic-
tion of repetitions of an experiment was evaluated. In each laboratory,
two repetitions were sufﬁcient to come to a prediction in 35/36 exper-
iments, so that concordance between repetitions was optimal. For one
substance each laboratory had to conduct 3 repetitions, since the ﬁrst
and second repetition resulted in discordant conclusions.
3.2.2. Between-laboratory reproducibility (BLR)
The BLR was assessed by the concordance of predictions. According
to the PS, the mode prediction should be used when three independent
experimentswere available. As predictions of independent experiments
of the same substancewere concordant in all cases, this was straightfor-
ward. Note that due to the speciﬁc design of this study, 15 of the 20 ref-
erence substances were tested in three laboratories (lead, laboratories 1
and 2 or lead, laboratories 3 and 4), while ﬁve substanceswere tested in
all ﬁve laboratories.
For all 20 references substances, concordant predictions between
laboratories were obtained. Consequently, the BLR of the LuSens was
20/20 = 100% (Table 5).
In addition, the concordance of prediction of repetitions of an exper-
iment was evaluated with this larger data set. As compared to the re-
spective analysis of the WLR, 34 experiments were added (lead: 8;
laboratory 3: 13; laboratory 4: 13). In ﬁve of these experiments (lead:
4; laboratory 3: 1), three repetitions had to be conducted to complete
the experiment. In total, in 94.4%, i.e. 134/142 of the experiments’ repe-
titions were reproducible.
3.2.3. Predictive capacity
The predictive capacity of the LuSens assay in this study was deter-
mined by comparing the LuSens predictions with the in vivo categories
as speciﬁed in the PS of the OECD (OECD, 2015), here referred to as ref-
erence results. Among the 20 test substances, there were 12 sensitizers
and 8 non-sensitizers. The lead laboratory was able to identify 11/12
sensitizers as true positive; while the laboratories 1, 2, 3 and 4 correctly
identiﬁed 7/8; 7/8; 6/6 and 6/6, respectively. Theweak sensitizer phenyl
benzoate was the only positive substance that was not properly identi-
ﬁed by the lead laboratory, laboratories 1 and 2. Laboratories 3 and 4 did
not test this test substance. Concerning the true negative substances,
the lead lab was able to identify correctly 6/8, whereas laboratories 1Table 4
Predictions of the three independent experiments with the 12WLR-reference substances of thr
tion; #: experiments conducted in the transferability phase; *: experiments with three repetiti
Test substances Lead
Exp1 Exp2 Exp3
2,4-Dinitrochlorobenzene + + +
4-Methoxy-acetophenone + + +
4-Nitrobenzylbromide + + +
Citral + + +
Ethylene glycol dimethacrylate + + +
Glycerol − − −
Isoeugenol + + +
Isopropanol − −* −
Methyldibromo glutaronitrile + + +
Para-phenylenediamine + + +
Phenyl benzoate − − −
Salicylic acid − − −and 2 identiﬁed 3/4 and laboratories 3 and 4 identiﬁed 6/7 as true neg-
atives. 4-methoxy-acetophenone was tested in the lead laboratory and
laboratories 1 and 2 and it was not properly identiﬁed as negative in
all three laboratories. Methyl salicylate was tested and not properly
identiﬁed in the lead laboratory and laboratories 3 and 4 (Table 5 and
Table S2). In summary, of the eight non-sensitizers, 4-methoxy-
acetophenone and methyl salicylate were concordantly predicted as
sensitizers. Phenyl benzoate was concordantly miss-predicted as a
non-sensitizer.
The accuracy of the LuSens assay based on the OECD PS for assays
similar to ARE–Nrf2 luciferase testmethods, was good in all laboratories
with accuracy ranging among the laboratories from 83–92%, with sensi-
tivities between 88–100% and speciﬁcity between 75–86% (Table 6).
This remarkable performance is comparable with the accuracy pre-
viously reported (Ramirez et al., 2014; Urbisch et al., 2015).
3.3. Similarity with KeratinoSens™
For the same set of test substances the LuSens and the
KeratinoSens™ assay showed accuracy of 85% (Table 7). Both assays
correctly predicted 17 of the total of 20 test substances and wrongly
predicted 3 test substances. Whereas the LuSens assay led to two FP
predictions (4-methoxy-acetophenone and methyl salicylate) and oneee laboratories (+: positive/skin sensitizer prediction;−: negative/non-sensitizer predic-
ons).
Lab1 Lab2
Exp1 Exp2 Exp3 Exp1 Exp2 Exp3
+ + + +# + +
+ + + + + +
+ + + + + +
+# + + +# + +
+# + + +# + +
− − − − − −
+ + + + + +
− − − − − −
+ + + + + +
+ + + + + +
− −* − −* − −
− − − − − −
Table 6
Accuracy of the LuSens assay for the OECD performance standards.
Laboratory
Lead 1 2 3 4
n 20 12 12 13 13
Sensitivity (%) 92 88 88 100 100
Speciﬁcity (%) 75 75 75 86 86
Positive predictive value (%) 85 88 88 86 86
Negative predictive value (%) 86 75 75 100 100
Accuracy (%) 85 83 83 92 92
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KeratinoSens™ assay led to one FP (4-methoxy-acetophenone) and two
FN predictions (eugenol and phenyl benzoate) (Table 7). Obviously,
LuSens and the KeratinoSens™ assays performed equally good, resulting
in 17 correct predictions out of 20 PS. Although previous reports support,
the functional redundancy of the LuSens and the KeratinoSens™ assay
(Natsch and Emter, 2015; Emter and Natsch, 2015), there is one sub-
stance with a different outcome in each assay, eugenol and methyl salic-
ylate. In either case, no strong or extreme sensitizer was under-predicted.
LuSens correctly predicted eugenol and only over-predicted one non-
sensitizer, methyl salicylate.
4. Discussion
4.1. Phase I: transferability to naïve laboratories
The results from Phase I indicate that the method is sufﬁciently ro-
bust that either a week on-site training or by means of the protocol
and teleconferences, was enough for successful transfer of the method.
The success of the transferabilitywas evaluated based on thepercentage
of non-qualiﬁed/invalid repetitions and on the predictive capacity of the
assay. The major problem encountered during this phase was the highTable 7
Comparison of predictivity among LuSens and KeratinoSens™ (data from the literature)
for the set of 20 test substances (NS: non-sensitizer; S: sensitizer; n.a.: not applicable;
+: positive/skin sensitizer prediction; -: negative/non-sensitizer prediction; PPV: positive
predictive value; NPV: negative predictive value).
Test substance LLNA reference result LuSens KeratinoSens™
NS vs
S
LLNA potency
4-Methoxy-acetophenone NS n.a. + +
Chlorobenzene NS n.a. − −
Glycerol NS n.a. − −
Isopropanol NS n.a. − −
Lactic acid NS n.a. − −
Methylsalicylate NS n.a. + −
Salicylic acid NS n.a. − −
Sulfanilamide NS n.a. − −
2-Mercaptobenzothiazole S Moderate + +
2,4-Dinitrochlorobenzene S Extreme + +
4-Methylaminophenolsulfate S Strong + +
4-Nitrobenzylbromide S Extreme + +
Citral S Moderate + +
Ethylene glycol
dimethacrylate
S Weak + +
Eugenol S Weak + −
Isoeugenol S Moderate + +
Methyldibromo glutaronitrile S Strong + +
Oxazolone S Extreme + +
Para-phenylenediamine S Strong/extreme + +
Phenyl benzoate S Weak − −
Total number 20 20
Sensitivity (%) 91.7 83.3
Speciﬁcity (%) 75.0 87.5
PPV (%) 84.6 90.9
NPV (%) 85.7 77.8
Accuracy (%) 85.0 85.0toxicity observed in some laboratories for the PC, even to levels below
70% viability. Since the purpose of the PC is to ensure that the system
is sensitive enough to be activated by weak sensitizers, laboratories
were permitted to adjust the concentration of the PC in such a way
that the criterion related to luciferase induction N2.5 folds compared
to vehicle control could be met without compromising the viability of
the cells. In this context, a new criterion to control the toxicity of the
PC was established and used for Phase II testing. During Phase I there
was uncertainty among the testing laboratories to know when to stop
testing; this was especially relevant in the case of non-concordant rep-
etitions. For this purpose, the protocol was further amended to provide
clearer guidance on when to re-test and when to stop testing.
With a percentage of valid repetitions N75%, all laboratories adopted
the method successfully.
Another aspect calling for method reﬁnement was identiﬁed when
two testing laboratories (laboratories 3 and 4) reported low RLUs
using the Steady-Glo® Assay System speciﬁed in the protocol. The
lead lab was asked to explore an alternative system, such as the One-
Glo™ system (also developed by Promega) which contains a different
luciferase substrate that provides a more robust system and higher
RLUs. The lead lab had already evaluated the One-Glo™ system and
found it to be comparable to the Steady-Glo® system with no impact
on the performance of the LuSens Assay (Ramirez et al., 2014). As
such, the protocol was amended to include the use of OneGlo™ system.
4.2. Phase II: assessment of reproducibility and reliability
Regarding the WLR, the LuSens assay met the PS requirement
(WLR ≥ 80%) in each of three laboratories that performed testing for
WLR (lead, laboratories 1 and 2). The same was true for the BLR,
which was of 100% when evaluating the data for all 20 PS distributed
in all participating laboratories. This data demonstrate the robustness
and reliability of the method.
The LuSens assay was able to correctly identify the sensitization po-
tential of 17 of 20 PS, with two FP substances, 4-methoxy-acetophenone
and methyl salicylate, and one FN, phenyl benzoate. It is important to
note that 4-methoxy-acetophenone has been also reported as a FP in
the KeratinoSens™ (OECD TG 442D, 2015). Phenyl benzoate, a weak sen-
sitizer according to the LLNA, was concordantly misclassiﬁed as a non-
sensitizer, as with KeratinoSens™ (OECD TG 442D, 2015; Natsch et al.,
2011). Phenyl benzoate is an acyl transfer agent, which preferably inter-
acts with lysine residues rather than cysteine residues. As indicated in
the study of Urbisch and coworkers, the ARE-activating assays, present
poor accuracy to such type of agents, most likely speciﬁc for reactivity
with NH2 groups, a reason for not reacting with KeapI and concomitantly
it does not activate ARE-dependent gene activity (Urbisch et al., 2015).
The reason for the FP predictions of 4-methoxy-acetophenone in both
ARE–Nrf2-luciferase assays is unknown. It is considered a true FP.
Consequently, the accuracy of the LuSens assay based on 20 PS was
85.0% the sensitivity was 91. 7% and the speciﬁcity was 75.0%. The spec-
iﬁcity appears low due to the over prediction of 2 substances in a rela-
tively small substance set of 8 non-sensitizers among the PS; one of
which showed borderline read-outs and one was consistently FP in
LuSens and KeratinoSens™. It is important to note that when assessing
the speciﬁcity, sensitivity and accuracy of the LuSens assay using a larger
set of test substances (Urbisch et al., 2015), values above 80% were ob-
tained in all cases. The PS requirement that no strong or extreme sensitiz-
er should be under-predicted as non-sensitizer was fulﬁlled. Altogether,
the LuSens assay has fulﬁlled the requirements for the assessment of pro-
posed similar or modiﬁed in vitro skin sensitization ARE–Nrf2 luciferase
test methods to be considered as a ‘me-too’ assay (OECD, 2015).
4.3. Similarity with KeratinoSens™
As previously suggested (Natsch and Emter, 2015), the LuSens assay
and the KeratinoSens™ assay are functionally equal. Both assays
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tion. A comparison of data for 69 substances tested in both assays result-
ed in 88% concordance of classiﬁcations (Urbisch et al., 2015). In the
present study, the comparison of both assays with the 20 PS tested in
Phase II resulted in the same accuracy of 17/29 (85%). Both assays
misclassiﬁed 3 of the 20 PS; the LuSens assay with two FP and one FN,
and the KeratinoSens™ assay with one FP and two FN substances
(Table 7). Both assays misclassiﬁed 4-methoxy-acetophenone and phe-
nyl benzoate. In addition, LuSens misclassiﬁed methyl salicylate and
KeratinoSens™ misclassiﬁed eugenol. However, it is to notice that in
the KeratinoSens™ interlaboratory validation study some participating
laboratories reported this test substance as positive.
Eugenol has been properly identiﬁed in the LuSens assay with high
reproducibility during the intra-laboratory validation of the study, as
well as the inter-laboratory validations, exhibiting values considerably
above the threshold.
Methyl salicylate is in general considered as a TN substance, howev-
er, some human evidence suggest certain sensitization potential
(ICCVAM, 2010; Emter et al., 2010). As presented by Natsch and co-
workers in the KeratinoSens™ interlaboratory validation study, this
test substance was evaluated as TN (Natsch et al., 2011), however, it is
worth noticing that non-concordant repetitions were also reported for
this test substance. This suggests that the evaluation of this test sub-
stance might be challenging when using ARE-activating assays. Espe-
cially since the misclassiﬁcation could be the result of borderline
readouts.
The LuSens assay (as does the KeratinoSens™ assay) addresses
keratinocyte activation, one step of the AOP for skin sensitization and
is in general not intended as a stand-alone method to predict skin sen-
sitization in humans but rather to be used as part of a testing battery in
order to assess the sensitization potential of chemicals. The data pre-
sented here indicated that the method is transferable, robust and reli-
able for use in the identiﬁcation of potential skin sensitizers.
In order to strive for future use of the method in the regulatory
arena, the data presented here are under revision at EURL ECVAM.5. Conclusion
The LuSens assay underwent a validation study focused on the ful-
ﬁllment of the performance standards deﬁned by the OECD for similar
or modiﬁed in vitro skin sensitization ARE–Nrf2 luciferase test methods
based on the KeratinoSens™ assay. In total, ﬁve laboratories participat-
ed in the study that was designed to provide the information required
and minimize the testing burden of the laboratories. The assessment
of reliability and accuracy of the method was performed with the 20
PS adopted by the OECD.
Reproducibility of the LuSens in terms of concordance of predictions
within and between the laboratories was 100%, clearly meeting the re-
quirements set forth by the OECD.
The accuracy was the same for the LuSens and the KeratinoSens™
assay, 85%, for the same set of test substances. Each assay differed in
one false prediction out of the 20 PS; the LuSens assay over-predicted
methyl salicylate, KeratinoSens™ under-predicted eugenol. These data
suggest that the LuSens assay is a robust and reliablemethod to address
the molecular initiating event of skin sensitization. Most importantly,
the data provide relevant information to propose the LuSens method
as me-too method for its inclusion in the OECD TG442D.Transparency document
The Transparency document associated with this article can be
found in online version.
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